CME webinar series: Empowering Providers on Substance Use Disorders

Jun. 2025Education/Webinars

Register for our new CME webinar series: Empowering Providers on Substance Use Disorders

Join us for our upcoming CME webinar series, "Empowering Providers," designed to enhance your knowledge and skills in managing substance use disorders. This four-part series will provide you with the latest insights and evidence-based strategies to improve patient outcomes.

Overdose Prevention and Response Training

  • Join us on Aug. 26, 2025, from noon to 1 p.m., to learn how to recognize overdose risks and symptoms, respond effectively, and apply proven strategies to prevent patient overdose.

    Comprehensive Care for Alcohol Use Disorder

  • Join us on Sept. 9, 2025, from noon to 1 p.m., to explore the importance of screening for alcohol use disorder (AUD), learn how to use effective screening tools, and apply evidence-based treatment strategies to improve patient care.

    Comprehensive Care for Opioid Use Disorder

  • Join us on Sept. 30, 2025, from noon to 1 p.m., to explore the importance of screening for opioid use disorder (OUD), learn how to use effective screening tools, and implement evidence-based treatments to support recovery.

    Comprehensive Care for Tobacco Use Disorder

  • Join us on Nov. 12, 2025, from noon to 1 p.m., to learn how to recognize tobacco use disorder (TUD), use proven screening tools, and deliver evidence-based care to help patients quit tobacco successfully.

Register Now

Provider is responsible for verifying CME eligibility.

This activity is approved for the following credit: AMA PRA Category 1 Credit™, ANCC, ACPE, and ASWB. Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.


Recent Announcements

CME Webinar: The State of Telehealth in 2026

Please join us for a live, CME-accredited webinar on Tuesday, Jan. 27, from noon to 1 p.m. that will share updates on the state of telehealth for 2026.
Dec. 2025Education/Webinars

Formulary updates effective Jan. 1, 2026

Review upcoming policy and operational updates
Dec. 2025Pharmacy Updates

Voluntary nationwide recall: Famotidine (Fresenius – November)

Fresenius Kabi USA, LLC is recalling three lots (6133156, 6133194, and 6133388) of Famotidine Injection, USP, 20 mg per 2 mL. Famotidine is used to treat excessive secretion of stomach acid or stomach ulcers.
Nov. 2025Pharmacy Updates